Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Clarametyx Biosciences announced that CMTX-101, a monoclonal antibody designed to collapse bacterial biofilms, will receive ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

The Citi Strata Elite was built to compete with some of the most popular travel credit cards, and its $595 annual fee ...

Kenya’s National Land Policy is undergoing a review, providing an opportunity to the state to officially recognise ...

Dharmani stated that innovative initiatives are being undertaken to enhance the skills of young people and promote ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA reviews odronextamab's application for relapsed lymphoma, highlighting trial enrollment issues but confirming safety and efficacy.

A Cordova Mall restaurant was temporarily closed during its latest inspection after an inspector found rodent droppings, live ...

The Indoor Football League acknowledged there was a judgment error by officials in the review process on the last play of the Rattlers' 49-48 playoff loss to the San Diego Strike Force on Aug. 4 at ...

“We’re grateful to Minimax Express for their generosity and for using their platform (literally) to help spread the word,” ...